source
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…
- Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027Moonwalk Biosciences, an obesity drug developer backed by Eli Lilly, announced a $70 million Series B financing. The funding will support its lead RNAi candidate, MW101, which in mouse studies pro…